RESEARCH ARTICLE

Open Access



Anatomic stemless shoulder arthroplasty and related outcomes: a systematic review

Nael Hawi^{1,2*}, Mark Tauber^{1,3}, Michael Joseph Messina^{1,4}, Peter Habermeyer¹ and Frank Martetschläger^{1,5}

Abstract

Background: The latest generation of shoulder arthroplasty includes canal-sparing respectively stemless designs that have been developed to allow restoration of the glenohumeral center of rotation independently from the shaft, and to avoid stem-related complications. The stemless prosthesis design has also recently been introduced for use in reverse arthroplasty systems.

Methods: We systematically reviewed the literature for studies of currently available canal-sparing respectively stemless shoulder arthroplasty systems. From the identified series, we recorded the indications, outcome measures, and humeral-sided complications.

Results: We identified 11 studies of canal-sparing respectively stemless anatomic shoulder arthroplasty implants, published between 2010 and 2016. These studies included 929 cases, and had a mean follow-up of 26 months (range, 6 to 72 months). The rates of humeral component-related complications ranged between 0 and 7.9 %. The studies reported only a few isolated cases of complications of the humeral component. Some arthroplasty systems are associated with radiological changes, but without any clinical relevance.

Conclusions: All of the published studies of canal-sparing respectively stemless shoulder arthroplasty reported promising clinical and radiological outcomes in short to midterm follow-up. Long-term studies are needed to demonstrate the long-term value of these kind of implants.

Keywords: Shoulder arthroplasty, Stemless, Canal-sparing, Total shoulder arthroplasty, Shoulder arthritis, Posttraumatic shoulder arthritis

Abbreviations: ER, external rotation; IR, internal rotation; CTA, cuff tear arthropathy; MRCT, massive rotator cuff tear; VAS, Visual Analog Scale; SPADI Index, Shoulder Pain and Disability Index; DASH Score, Disabilities of the Arm, Shoulder and Hand Score; ASES Score, American Shoulder and Elbow Surgeons Shoulder Score; WOOS Index, Western Ontario Osteoarthritis Shoulder Index; e.g., For example; etc., Et cetera

Background

Early development of shoulder arthroplasty can be traced back to 1950s when Charles Neer, II, described the use of an implant to treat a proximal humeral fracture [1]. Eventually, the indication was widened to include osteoarthritis treatment. Since Neer's initial prosthesis, the humeral stem design has undergone several changes. Results of total shoulder arthroplasty were first presented in 1974 [2]. The following years saw the introduction of several

variations of stemmed humeral implants, which could be subdivided into four different generations. Stem design initially used a monoblock system, then changed to a modular system, followed by a shift to the use of shorter stems. Additionally, cemented fixation techniques have been replaced over time by a press-fit cementless system. The use of shorter implant stems and the elimination of humeral cement carry several advantages, including the preservation of humeral bone stock for potential revisions, performance of anatomic reconstruction regardless of posterior offset in anatomic arthroplasty, facilitating arthroplasty in cases of humeral deformity, prevention of malpositioning, and avoiding periprosthetic fractures [3].

Full list of author information is available at the end of the article



^{*} Correspondence: hawi.nael@mh-hannover.de

¹Department of Shoulder and Elbow Surgery, ATOS Clinic Munich, Effnerstraße 38, 81925 München, Germany

²Trauma Department, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany

Commonly reported stem-related complications include intraoperative humeral fracture, loosening, stress shielding, and traumatic periprosthetic fracture [4–11]. Fracture sequelae, including severe shaft-head malunion, can lead to malalignment of the shaft implantation and a failure to restore the anatomic center of rotation. In revision surgery, stem removal can present a challenge for the surgeon, potentially requiring an osteotomy or inadvertently resulting in an intraoperative fracture [5, 6, 8, 11]. Canal-sparing respectively stemless prostheses were first available in Europe in 2004. Such implants lack a conventional diaphyseal humeral stem, are based on metaphyseal fixation, and do not violate the humeral canal. In this review article, the terms "canal-sparing" respectively "stemless" refer to implant designs with metaphyseal fixation using a standard humeral neck cut, and excluding humeral head resurfacing techniques. Canalsparing respectively stemless shoulder arthroplasty must not be confused with resurfacing techniques that aim to restore joint congruency by preserving the majority of the humeral head bone stock and implantation of a metallic cap over the remaining humeral head bone stock [3, 12-18].

Here we have systematically reviewed the current literature describing canal-sparing respectively stemless prostheses in shoulder arthroplasty, particularly with regards to clinical outcomes and complications related to the humeral components.

Methods

The senior investigator (FM) and first author (NH) systematically scanned an online database system (Pubmed, Google Scholar) using the MeSH terms "stemless", "shoulder replacement", "shoulder arthroplasty", "canal-sparing", and "short stem". Then the resulting list of references was

reviewed to identify potential additional studies. Inclusion criteria were clinical studies including more than five patients, using cementless and stemless humeral fixation, and presenting outcomes and complications.

Statistical analysis was ineffective due to the small number of cases, as well as the use of different follow-up protocols, study designs, and outcome measures. Therefore, we performed a descriptive review, with information presented according to the different investigated prosthetic designs. For all included series, we recorded and summarized the indications, outcome measures (clinical and radiological), and complications. The scoring systems of the different studies are presented systematically. Only complications related to the humeral component are included.

Results

Our findings are summarized in Tables 1, 2, 3, 4 and 5.

Biomet Total Evolutive Shoulder System

The first available canal-sparing respectively stemless implant was the Biomet Total Evolutive Shoulder System (TESS, Biomet, Warsaw, IN, USA), which was first used in Europe in 2004 (Fig. 1). The TESS is a three-component system, which includes an impaction-implanted 6-armed corolla that is porous to improve bone ingrowth. We identified five studies using the TESS, which were published between 2010 and 2016, and included a total of 155 patients. Follow-up times ranged from 6 to 45 months. Table 2 presents the surgical indications. All studies showed clinical improvement after arthroplasty compared to the preoperative status.

In 2010, Huguet et al. [19] first reported on 63 cases with a minimum follow-up of three years. Concerning the TESS stemless humeral implant, the authors report that in five cases the lateral cortex cracked during

Table 1	Included	patients	and	follow-up

			Implant	n = included stemless	Age (years, mean)	FU (months, mean)
2010	Huguet et al.	JSES	TESS	63	64	45.2
2013	Razmjou et al.	JSES	TESS	17	69	24
2013	Berth et Pap	JOT	TESS	41	67	30.8
2015	Maier et al.	BMC	TESS	12	68	6
2011	Kadum et al.	AOTS	TESS	22	71	14
2014	Bell et Coghlan	Int J Shoulder Surg	Mathys Affinis	38	68	12
				12	65	24
2011	Schoch et al.	Obere Extremitaet	Arthrex Eclipse	96	66	13.2
				19	62	
2012	Brunner et al.	Obere Extremitaet	Arthrex Eclipse	233	61	23.2
2015	Habermeyer et al.	JSES	Arthrex Eclipse	78	58	72
2016	Ho et al.	JSES	Simpliciti	149	66	24
2016	Churchill et al.	JBJS	Simpliciti	149	66	24

Page 3 of 10

 Table 2 Indication for stemless arthroplasty treatment

		Implant	N (stemless)	Primary osteoarthritis	Posttraumatic osteoarthritis	Osteo- necrosis	Rheumatoid arthritis	СТА	MRCT	Instability arthritis	Post infection arthtis	Arthritis due to glenoid dysplasia	Revision	
2010 Huguet et al.	JSES	TESS	63	60		3								
2013 Razmjou et al.	JSES	TESS	17	17										
2013 Berth et Pap	JOT	TESS	41	41										
2015 Maier et al.	BMC	TESS	12	12										
2011 Kadum et al.	AOTS	TESS	22	19			3							
2014 Bell et Coghlan	Int J Shoulder Surg	Mathys Affinis	50	50										
2011 Schoch et al.	Obere Extremitaet	Arthrex Eclipse	115	96	19									
2012 Brunner et al.	Obere Extremitaet	Arthrex Eclipse	233	100	70	6	16	3		29	4			5 cases couldn't assigned
2015 Habermeyer et al.	JSES	Arthrex Eclipse	78	39	26			3		8	1	1		
2016 Ho et al.	JSES	Simpliciti	149											Not specified
2016 Churchill et al.	JBJS	Simpliciti	149	96 %	4 %									

Table 3 Kind of stemless arthroplasty treatment and approach

			Implant	n	Approach	Hemiarthroplasty	Total shoulder arthroplasty	
2010	Huguet et al.	JSES	TESS	63	Deltopectoral	44	19	
2013	Razmjou et al.	JSES	TESS	17	Deltopectoral		17	
2013	Berth et Pap	JOT	TESS	41	Deltopectoral		41	
2015	Maier et al.	BMC	TESS	12	Deltopectoral		12	
2011	Kadum et al.	AOTS	TESS	22	Antero-Superior (Mackenzie)			Not assigned
2014	Bell et Coghlan	Int J Shoulder Surg	Mathys Affinis	50	Deltopectoral		50	
2011	Schoch et al.	Obere Extremitaet	Arthrex Eclipse	115	Deltopectoral		115	
2012	Brunner et al.	Obere Extremitaet	Arthrex Eclipse	233	Deltopectoral	114	119	
2015	Habermeyer et al.	JSES	Arthrex Eclipse	78	Deltopectoral	39	39	
2016	Ho et al.	JSES	Simpliciti	149	Deltopectoral		149	
2016	Churchill et al.	JBJS	Simpliciti	149	Deltopectoral		149	

surgery without any sign of instability, and that each of these cases healed without further intervention. No other humeral implant-associated complications or problems were noted.

The remaining four identified studies reported no complications related to the TESS humeral implant. Kadum et al. [20] analyzed 56 patients, among whom 22 received an anatomic TESS prosthesis, with a mean follow-up of 14 months. Razmjou et al. [21] compared the anatomic TESS prosthesis (n = 17) to the Bigliani-Flatow (n = 40) and the Neer II prosthesis (n = 22), showing no significant

differences in outcome between groups, with a mean follow-up of 24 months. Berth and Pap [22] compared the anatomic TESS prosthesis to the Mathys Affinis stemmed prosthesis, with 41 patients in each group and a mean follow-up of 30 months. Their results revealed no statistically significant differences in outcome. Finally, Meier et al. [23] compared the anatomic TESS prosthesis to the anatomic stemmed Aequalis Shoulder prosthesis (Tournier, Lyon, France), with 12 cases per group and a 6-month follow-up. They reported comparable results for both groups based on the Constant Score.

Table 4 Humeral implant related complication

			Implant	n	Percentage of complication	Kind of stemless humeral implant related complication and treatment
2010	Huguet et al.	JSES	TESS	63	7.9 %	- Five patients with a small crack of the humeral lateral cortex intraoperatively, noticed on the first postoperative radiograph, further conservative treatment
2013	Razmjou et al.	JSES	TESS	17	0 %	-
2013	Berth et Pap	JOT	TESS	41	0 %	-
2015	Maier et al.	BMC	TESS	12	0 %	-
2011	Kadum et al.	AOTS	TESS	22	0 %	-
	Bell et Coghlan	Int J Shoulder Surg	Mathys Affinis	50	0 %	-
2011	Schoch et al.	Obere Extremitaet	Arthrex Eclipse	115	0 %	-
2012	Brunner et al.	Obere Extremitaet	Arthrex Eclipse	233	2.3 %	- One patient with radiological and asymptomatic loosening after 24 months
	Habermeyer et al.	JSES	Arthrex Eclipse	78	0 %	-
2016	Ho et al.	JSES	Simpliciti	149	0 %	-
2016	Churchill et al.	JBJS	Simpliciti	149	0 %	-

Table 5 Outcome parameters with radiological humeral conspicuous findings (values are given in mean if not declared different)

2010	Huguet et al.	JSES	TESS	63	Const score	ant	Anteri active elevat		ER wi elbow the si	v to	Radiological humeral component outcome
					29.6	75	96	145	20	40	Inconspicuous
013	Razmjou et al.	JSES	TESS	17	Quick	dash	WOOS	5	ASES		Inconspicuous
					54	23	37	85	41	82	
					Relati Const Murle Score	ant- y	Flexio	n (°)	Abdu (°)	ction	
					37	92	69	135	51	121	
					ER in neutra	al (°)	ER 90° abduc (°)		IR at 9 abdud (°)		
					18	54	9	61	1	33	
					Streng (lbs)	gth					
					5	10					
2013	Berth et Pap	JOT	TESS	41	DASH (point	score ss)	Consta score, adjust (point	ed	Antev (°)	ersion	Inconspicuous
					62.1	47.4	40.1	73.2	81.2	115.9	
					Abdu (°)	ction	Extern rotatio				
					68.2	105	39.1	54.4			
015	Maier et al.	BMC	TESS	12	Const score	ant	Flexio	n (°)	Abdu (°)	ction	-
					33.7	48	94.2	96.9	79.6	85.9	
011	Kadum et al.	AOTS	TESS anatomic	22	Quick	dash	EQ-5D)	VAS fo		Inconspicuous
			TESS reverse	17							
					56	34	0.36	0.73	39	66	
2014	Bell et Coghlan	Int J Shoulder Surg	Mathy Affinis	50	Const score	ant	DASH	score	ASES	score	Inconspicuous
				38	28.84	76.12	49.36	10.79	42.51	88.28	
				12	24.82	85.75	48.80	5.94	46.39	92.58	
					SPAD	l score	Active elevat (media	ion			
				38	64.28	11.05	75	160			
				12	60.63	5.16	93.18	160			
2011	Schoch et al.	Obere Extremitaet	Arthrex Eclipse	115	Const Murle score		Antev (°)	ersion	Abdu (°)	ction	Inconspicuous
				96	44.7	66	118	145	82	105	
				19	34.6	57	110	140	75	100	
				Exterr rotation							
				96	15	41					

Table 5 Outcome parameters with radiological humeral conspicuous findings (values are given in mean if not declared different) (*Continued*)

				19	15	38					
2012 Brunner et al.	Obere Extremitaet	Arthrex Eclipse	233	Constant Murley score (%)		Flexio	n (°)	Abdud (°)	ction	7.2 % of cases radiolucency between the head and the screw without clinical consequences	
					51.6	78.9	105	128	80	120	
					Externa rotation						
					22	37					
2015	Habermeyer et al.	JSES	Arthrex Eclipse	78	Constant Murley score (%)		Flexion (°)		Abduction (°)		Incomplete radiolucent line of the humeral compone smaller than 2 mm in one patient, in three patients partial osteolyses under the superior part of the
					38.1	75.3	114	141	74	130	humeral component without loosening, decreased density of cancellous bone in the greater tuberosity
					Externa rotation						with the AP view in 34.9 % without influence on shoulder function.
					25	44					
2016	Ho et al.	JSES	Simpliciti	149	Constant Murley score (adjusted)		Constant Murley score (adjusted)		Constant Murley score (adjusted)		Inconspicuous
					<60 y		60-69	у	>70 y		
					51.2	90.5	55.9	105.6	58.2	110.6	
					ASES s	core	ASES :	score	ASES :	score	
					<60 y		60–69	У	>70 y		
					33.2	84.1	39.6	94.3	39.1	93.1	
					Simple should test		Simple should test		Simple should test		
					<60 y		60-69	у	>70 y		
					4	10.1	4.3	11	4.6	10.7	
					Externa		Extern		Extern		
					<60 y		60-69	У	>70 y		
					35.4	54.9	28.8	55.8	31.3	58.2	
					Scapula plane (Scapu plane		Scapu plane		
					<60 y		60-69	У	>70 y		
					107.1	142.4	102.3	149.6	100.9	144.5	
2016 Churchill et al.	JBJS	Simpliciti	npliciti 149	Murley Score	Murley score adjusted,		ASES score		e der	Inconspicuous	
							38.2	91.9	4.3	10.8	
					Pain VA Score	AS	Scapu plane		Eterna rotatio		
					5.9	0.5	102.8	146.6	30.9	56.4	

Mathys Affinis Short Stemless Prosthesis

The Mathys Affinis Short Stemless Prosthesis (Mathys, Betlach, Switzerland) was first available on the European

market in 2009 (Fig. 2). This arthroplasty system has two components: a humeral metaphyseal implant and a ceramic humeral head. The metaphyseal implant comprises four



Fig. 1 The Biomet Total Evolutive Shoulder System (TESS; Biomet, Warsaw, IN, USA) (Figure provided by the manufacturer)

wings composed of a rough porous titanium structure, with an osteoconductive calcium phosphate coating to improve bone ingrowth. This part is inserted with impaction.

In the only published study using this implant, Bell and Coghlan [24] investigated 50 cases with an indication of primary osteoarthritis. They reported a 24-month follow-up for 12 cases, and a 12-month follow-up for 38 cases. No prosthesis-related intraoperative or postoperative complications were reported.

Arthrex Eclipse Prosthesis

The Arthrex Eclipse Prosthesis (Arthrex, Naples, USA) was introduced in 2005 (Fig. 3). This prosthesis comprises three components. A fully threaded, cylindrical



Fig. 2 The Mathys Affinis Short Stemless Prosthesis (Mathys, Betlach, Switzerland) (Figure provided by the manufacturer)



Fig. 3 The Arthrex Eclipse Prosthesis (Arthrex, Naples, USA) (Figure provided by the manufacturer)

central cage unit is inserted over a collar-bearing baseplate (trunnion) for metaphyseal fixation. The trunnion covers the resection plane at the anatomical neck, and joins cortical support. The third component is a corresponding humeral head. In contrast to the other described implants, the Arthrex Eclipse is the only available stemless system that offers screw-in insertion.

Between 2011 and 2015, three studies investigated the Eclipse prosthesis, including a total of 426 procedures with a mean follow-up ranging from 13 to 72 months. Table 2 presents the specific surgical indications. Schoch et al. [25] analyzed 115 cases, and reported that all of the radiographs evaluated at the 12-month follow-up were inconspicuous with regards to loosening or radiolucent lines. Brunner et al. [26] published their experience of using the Eclipse prosthesis in 233 patients after a mean follow-up of 23 months. They describe one case in which the implant loosened after 24 months, and they noted radiolucency between the head and the screw in 7.2 % of cases. However, these radiological changes did not appear to have any clinical relevance.

In the most recent study of the Eclipse prosthesis, Habermeyer et al. [27] analyzed 78 patients with a minimum follow-up of 5 years. They reported that one patient showed an incomplete radiolucent line of the humeral component of smaller than 2 mm. Additionally, three patients exhibited partial osteolysis under the superior part of the humeral component, without loosening of the component. Among the patients, 34.9 % showed changed cancellous bone density in terms of stress shielding at the greater tuberosity on the AP view, without clinical significance. No implant-specific complications were observed related to the Eclipse prosthesis.



Fig. 4 The Simpliciti Stemless Prosthesis (Tornier, Bloomington, MN, US) (Figure provided by the manufacturer)

Simpliciti Stemless Prosthesis

Clinical use of the Simpliciti Stemless Prosthesis (Tornier, Bloomington, MN, US) began in France in 2010 (Fig. 4). It is presently the only FDA-approved stemless respectively canal-sparing implant. It comprises two pieces—a humeral implant and a head implant—which are available in different sizes. Churchill et al. [27] and Ho et al. [18, 28] both recently published results of canal-sparing respectively stemless shoulder arthroplasty with a 24-month follow-up in a total of 298 patients. Table 2 summarizes the indications. Both studies demonstrated improved outcomes, and no humeral-sided complications.

Discussion

Six different canal-sparing respectively stemless humeral implants are presently available on the market, four of which are described in published studies. The canal-sparing respectively stemless shoulder prosthesis with metaphyseal anchoring is a relatively new concept that reportedly provides good outcomes that are comparable to stemmed designs in short and midterm evaluations [19, 21–23, 27]. All of the presently reviewed studies demonstrated substantial improvement after replacement. Moreover, the studies that compared the canal-sparing respectively stemless design to stemmed implants showed no differences in outcomes related to the humeral component [21–23].

The indications for canal-sparing respectively stemless prosthesis are the same as for stemmed systems. Canal-sparing respectively stemless implants cannot be used in cases with poor bone quality, metaphyseal cysts, osteopenia, osteoporosis, or other metabolic bone diseases [29], or in cases with fractures in the metaphyseal area that disturb adequate bony in-growth or primary implant stability.

However, there is not yet any test available to objectively determine bone quality pre- or intraoperatively [29]. Churchill et al. [18] described the use of a "thumb test" in which bone quality is intraoperatively assessed by compressing the surface of the neck cut with the thumb. Overall, the presently reviewed studies reported only a few isolated cases of loosening of the stemless component.

Among the various investigated canal-sparing respectively stemless prostheses, the main difference in design is that the Eclipse is inserted over a screw, while the TESS, the Simpliciti, and the Affinis prostheses are inserted using an impaction technique. It appears that the mechanism of force transmission when the Eclipse prosthesis is inserted over a screw differs from that during impaction implantation of the corolla of the TESS, the wings of the Affinis, or the Simpliciti prosthesis. This difference may explain the observed differences in the surrounding humeral bone, with changed bone mineral density seen on radiographs, which could be interpreted as stress shielding beneath the trunnion with the Eclipse prosthesis. These findings are not correlated with any negative clinical symptoms, and seem to be purely a radiographic phenomenon, at least at the midterm follow-up. Subgroup analysis of these patients reported by Habermeyer et al. [27] revealed no statistical significance in the patient cohort, with a minimum follow-up of 5 years.

One major advantage of the canal-sparing respectively stemless prosthesis design is that it can potentially be used in post-traumatic and deformity cases regardless of the humeral head-shaft configuration. Restoration of the glenohumeral center of rotation independently from the shaft is a key goal in secondary shoulder arthroplasty for fracture sequelae treatment [30]. Malunion resulting in metaphyseal-diaphyseal malalignment can make it difficult or even impossible to implant a stemmed or even a short-stemmed prosthesis. In such cases, corrective osteotomies are associated with poor results [31]. Reports of these types of special cases are limited to only rare single cases within the studies. Other advantages of the canalsparing respectively stemless prosthesis are that it can preserve bone stock of the proximal humerus, as well as avoid humeral stem-related complications in revision cases requiring stem removal. In a commentary, Athwal summarized the advantages of the canal-sparing respectively stemless implant as a theoretically decreased surgical time, less blood loss, bone preservation, and lower risk of intraoperative and potentially postoperative periprosthetic fractures. Canal-sparing respectively stemless prostheses are also suitable for posttraumatic joint reconstruction and, when needed, explantation is easier compared to with the stemmed version. Following explantation, a stemless prosthesis can be replaced by a standard-length primary implant [29].

For the purpose of this review, we chose to include all available literature evaluating anatomic canal-sparing respectively stemless humeral components in shoulder arthroplasty. This review article refers to only implant designs with metaphyseal fixation, and excludes humeral head resurfacing. It is much easier to achieve glenoid exposure for glenoid component implantation using canal-sparing respectively stemless implants compared to with humeral head resurfacing [3, 20].

It must be noted that, all reviewed studies provide only short or midterm results, and include only a limited number of patients. Additionally, some studies were reported by the designer or co-developer of the investigated implant, which suggests the possibility of a certain bias. There are presently ongoing IDE trials, which will provide more robust and high-quality data on this topic.

Conclusions

All of the published studies describing anatomic canalsparing respectively stemless shoulder replacement showed promising clinical and radiological outcomes over short to midterm follow-up periods. To date, the available literature lacks well-designed clinical studies with at least midterm results.

Disclaimer

Peter Habermeyer receives patent fees for the Eclipse prosthesis from Arthrex, Inc. Mark Tauber and Frank Martetschläger are consultants for Arthrex, Inc. The other authors certify that they have no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/ licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article. Arthrex, Mathys, Tornier, and Zimmer Biomet own the copyrights and all other intellectual property rights related to the included pictures. All pictures are published with permission from Arthrex, Mathys, Tornier (an indirect subsidiary of Wright Medical Group N.V.), and Zimmer Biomet. This review article received no financial support, and Arthrex, Mathys, Tornier, and Zimmer Biomet are not responsible for the content of the review article aside from giving permission for the use of their photos.

Availability of data and materials

The authors are willing to share primary data related to this research upon request, presented in an additional file in a machine-readable format.

Authors' contributions

NH, MT, and FM designed the study, collected and analyzed the data, wrote the initial draft, and ensured the accuracy of the data and analysis. MM designed the study, analyzed the data, wrote the initial draft, and ensured the accuracy of the data and analysis. PH designed the study and ensured the accuracy of the data and analysis. All authors read and approved the final manuscript.

Competing interest

Peter Habermeyer receives patent fees for the Eclipse prosthesis from Arthrex, Inc. Mark Tauber and Frank Martetschläger are consultants for Arthrex, Inc. The other authors certify that they have no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article.

Arthrex, Mathys, Tornier, and Zimmer Biomet own the copyrights and all other intellectual property rights related to the included pictures. All pictures are published with permission from Arthrex, Mathys, Tornier (an indirect subsidiary of Wright Medical Group N.V.), and Zimmer Biomet. This review article received no financial support, and Arthrex, Mathys, Tornier, and

Zimmer Biomet are not responsible for the content of the review article aside from giving permission for the use of their photos.

Consent to publish

Not applicable

Ethics and consent to participate

Not applicable

Financial competing interests

Peter Habermeyer receives patent fees for the Eclipse prosthesis from Arthrex, Inc. Mark Tauber and Frank Martetschläger are consultants for Arthrex, Inc. The other authors certify that they have no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article.

Author details

¹Department of Shoulder and Elbow Surgery, ATOS Clinic Munich, Effnerstraße 38, 81925 München, Germany. ²Trauma Department, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. ³Department of Traumatology and Sports Injuries, Paracelsus Medical University, Salzburg, Austria. ⁴Boston Shoulder Institute/Harvard Medical School, Boston, MA, USA. ⁵Department of Orthopaedic Sports Medicine, Klinikum rechts der Isar, Technical University, Munich, Germany.

Received: 25 June 2016 Accepted: 24 August 2016 Published online: 30 August 2016

References

- Neer 2nd CS. Articular replacement for the humeral head. J Bone Joint Surg Am. 1955;37-A:215–28.
- Neer 2nd CS. Replacement arthroplasty for glenohumeral osteoarthritis. J Bone Joint Surg Am. 1974;56:1–13.
- Churchill RS. Stemless shoulder arthroplasty: current status. J Shoulder Elbow Surg. 2014;23:1409–14. doi:10.1016/j.jse.2014.05.005.
- Athwal GS, Sperling JW, Rispoli DM, Cofield RH. Periprosthetic humeral fractures during shoulder arthroplasty. J Bone Joint Surg Am. 2009;91:594– 603. doi:10.2106/JBJS.H.00439.
- Bohsali KI, Wirth MA, Rockwood Jr CA. Complications of total shoulder arthroplasty. J Bone Joint Surg Am. 2006;88:2279–92. doi:10. 2106/JBJS.F.00125.
- Chin PY, Sperling JW, Cofield RH, Schleck C. Complications of total shoulder arthroplasty: are they fewer or different? J Shoulder Elbow Surg. 2006;15:19– 22. doi:10.1016/i.jse.2005.05.005.
- Deshmukh AV, Koris M, Zurakowski D, Thornhill TS. Total shoulder arthroplasty: long-term survivorship, functional outcome, and quality of life. J Shoulder Elbow Surg. 2005;14:471–9. doi:10.1016/j.jse.2005.02.009.
- Farng E, Zingmond D, Krenek L, Soohoo NF. Factors predicting complication rates after primary shoulder arthroplasty. J Shoulder Elbow Surg. 2011;20:557–63. doi:10.1016/j.jse.2010.11.005.
- Kumar S, Sperling JW, Haidukewych GH, Cofield RH. Periprosthetic humeral fractures after shoulder arthroplasty. J Bone Joint Surg Am. 2004;86-A:680–9.
- Sperling JW, Cofield RH, Rowland CM. Minimum fifteen-year follow-up of Neer hemiarthroplasty and total shoulder arthroplasty in patients aged fifty years or younger. J Shoulder Elbow Surg. 2004;13:604–13. doi:10.1016/ S1058274604001296.
- 11. Wirth MA, Rockwood Jr CA. Complications of total shoulder-replacement arthroplasty. J Bone Joint Surg Am. 1996;78:603–16.
- Levy O, Copeland SA. Cementless surface replacement arthroplasty of the shoulder. 5- to 10-year results with the Copeland mark-2 prosthesis. J Bone Joint Surg Br. 2001;83:213–21.
- Levy O, Copeland SA. Cementless surface replacement arthroplasty (Copeland CSRA) for osteoarthritis of the shoulder. J Shoulder Elbow Surg. 2004;13:266–71. doi:10.1016/S1058274604000229.
- Levy O, Funk L, Sforza G, Copeland SA. Copeland surface replacement arthroplasty of the shoulder in rheumatoid arthritis. J Bone Joint Surg Am. 2004;86-A:512–8.
- 15. Mullett H, Levy O, Raj D, Even T, Abraham R, Copeland SA. Copeland surface replacement of the shoulder. Results of an hydroxyapatite-coated

- cementless implant in patients over 80 years of age. J Bone Joint Surg Br. 2007;89:1466–9. doi:10.1302/0301-620X.89B11.18850.
- Al-Hadithy N, Domos P, Sewell MD, Naleem A, Papanna MC, Pandit R. Cementless surface replacement arthroplasty of the shoulder for osteoarthritis: results of fifty Mark III Copeland prosthesis from an independent center with four-year mean follow-up. J Shoulder Elbow Surg. 2012;21:1776–81. doi:10.1016/j.jse.2012.01.024.
- Alizadehkhaiyat O, Kyriakos A, Singer MS, Frostick SP. Outcome of Copeland shoulder resurfacing arthroplasty with a 4-year mean follow-up. J Shoulder Elbow Surg. 2013;22:1352–8. doi:10.1016/j.jse.2013.01.027.
- Churchill RS, Chuinard C, Wiater JM, Friedman R, Freehill M, Jacobson S, Spencer Jr E, Holloway GB, Wittstein J, Lassiter T, Smith M, Blaine T, Nicholson GP. Clinical and radiographic outcomes of the simpliciti canalsparing shoulder arthroplasty system: a prospective two-year multicenter study. J Bone Joint Surg Am. 2016;98:552–60. doi:10.2106/JBJS.15.00181.
- Huguet D, DeClercq G, Rio B, Teissier J, Zipoli B, Group T. Results of a new stemless shoulder prosthesis: radiologic proof of maintained fixation and stability after a minimum of three years' follow-up. J Shoulder Elbow Surg. 2010;19:847–52. doi:10.1016/j.jse.2009.12.009.
- Kadum B, Mafi N, Norberg S, Sayed-Noor AS. Results of the Total Evolutive Shoulder System (TESS): a single-centre study of 56 consecutive patients. Arch Orthop Trauma Surg. 2011;131:1623–9. doi:10.1007/s00402-011-1368-4.
- Razmjou H, Holtby R, Christakis M, Axelrod T, Richards R. Impact of prosthetic design on clinical and radiologic outcomes of total shoulder arthroplasty: a prospective study. J Shoulder Elbow Surg. 2013;22:206–14. doi:10.1016/j.jse.2012.04.016.
- Berth A, Pap G. Stemless shoulder prosthesis versus conventional anatomic shoulder prosthesis in patients with osteoarthritis: a comparison of the functional outcome after a minimum of two years follow-up. J Orthop Traumatol. 2013;14:31–7. doi:10.1007/s10195-012-0216-9.
- Maier MW, Lauer S, Klotz MC, Bulhoff M, Spranz D, Zeifang F. Are there differences between stemless and conventional stemmed shoulder prostheses in the treatment of glenohumeral osteoarthritis? BMC Musculoskelet Disord. 2015;16:275. doi:10.1186/s12891-015-0723-y.
- Bell SN, Coghlan JA. Short stem shoulder replacement. Int J Shoulder Surg. 2014;8:72–5. doi:10.4103/0973-6042.140113.
- Schoch C, Huth J, Aghajev E, Bauer G, Mauch F. Die metaphysär verankerte Prothese bei posttraumatischer und primärer Omarthrose. Obere Extremität. 2011;6:275–81. doi:10.1007/s11678-011-0137-x.
- Brunner UH, Fruth M, Rückl K, Magosch P, Tauber M, Resch H, Habermeyer P. Die schaftfreie Eclipse-Prothese – Indikation und mittelfristige Ergebnisse. Obere Extremität. 2012;7:22–8. doi:10.1007/s11678-011-0152-y.
- Habermeyer P, Lichtenberg S, Tauber M, Magosch P. Midterm results of stemless shoulder arthroplasty: a prospective study. J Shoulder Elbow Surg. 2015;24:1463–72. doi:10.1016/j.jse.2015.02.023.
- Ho AG, Gowda AL, Wiater JM. Stemless humeral component in total shoulder arthroplasty: 2-year age-related clinical outcomes. J Shoulder Elbow Surg. 2016. doi: 10.1016/j.jse.2016.02.023.
- Athwal GS. Spare the canal: stemless shoulder arthroplasty is finally here: commentary on an article by R. Sean Churchill, MD, et al.: "Clinical and radiographic outcomes of the simpliciti canal-sparing shoulder arthroplasty system. A prospective two-year multicenter study". J Bone Joint Surg Am. 2016;98:e28. doi:10.2106/JBJS.15.01350.
- Kadum B, Hassany H, Wadsten M, Sayed-Noor A, Sjoden G. Geometrical analysis of stemless shoulder arthroplasty: a radiological study of seventy TESS total shoulder prostheses. Int Orthop. 2015. doi: 10.1007/s00264-015-2935-z.
- Boileau P, Trojani C, Walch G, Krishnan SG, Romeo A, Sinnerton R. Shoulder arthroplasty for the treatment of the sequelae of fractures of the proximal humerus. J Shoulder Elbow Surg. 2001;10:299–308. doi:10. 1067/mse.2001.115985.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit

